Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 13/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | ACACA | Q13085 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.49 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255729 | 0.98 | PPARA (0.50) | ACLYPPARAACACBACACATTR | |
| SCHEMBL6255723 | 0.98 | PPARA (0.50) | ACLYPPARAACACBACACATTR | |
| SCHEMBL5520099 | 0.96 | PPARA (0.49) | ACLYPPARAACACBACACATTR | |
| SCHEMBL5521484 | 0.94 | ACLY (0.57) | ACLYPPARAACACBACACATTR | |
| Gemcabene SCHEMBL761631 | 0.93 | ACLY (0.55) | ACLYPPARAACACBACACATTR | |
| SCHEMBL6258161 | 0.91 | ACLY (0.53) | ACLYPPARAACACBACACATTR | |
| SCHEMBL5531453 | 0.91 | ACLY (0.59) | ACLYPPARAACACBACACATTR | |
| Gemcabene SCHEMBL528316 | 0.91 | ACLY (0.53) | ACLYPPARAACACBACACATTR | |
| Gemcabene SCHEMBL4184554 | 0.91 | ACLY (0.53) | ACLYPPARAACACBACACATTR | |
| SCHEMBL14269711 | 0.91 | ACLY (0.59) | ACLYPPARAACACBACACATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820428-B1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER LAMBERT CO (US) | 2000-05-10 | — | — | EP | claimed |
| US-5756544-A | ADMINISTERING TO LOWER LEVELS OF LOW DENSITY LIPOPROTEINS AND TO RAISE THE LEVELS OF HIGH DENSITY LIPOPROTEINS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| EP-0820428-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| WO-1996030328-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1651205-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | Warner-Lambert Company LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1539127-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009431-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005002557-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ETHER AND SELECTIVE COX-2 INHIBITOR AND USES THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0820428-B1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER LAMBERT CO (US) | 2000-05-10 | — | — | EP | disclosed |
| US-5783600-A | FOR ELEVATING HDL CHOLESTEROL; ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-07-21 | — | — | US | disclosed |
| US-5756544-A | ADMINISTERING TO LOWER LEVELS OF LOW DENSITY LIPOPROTEINS AND TO RAISE THE LEVELS OF HIGH DENSITY LIPOPROTEINS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5750569-A | LOWERING PLASMA LIPIDS | WARNER-LAMBERT COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0820428-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5648387-A | Carboxyalkylethers, formulations, and treatment of vascular diseases | WARNER-LAMBERT COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1996030328-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | ACLY 560/4885PPARA 33/4885ACACB 412/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | ACLY 1581/4885PPARA 22/4885ACACB 608/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | ACLY 1982/4885PPARA 224/4885ACACB 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.